Citius Oncology Inc. - CTOR Total Company Value-to-Revenue Ratio

Official company branding of Citius Oncology (CTOR)

The EV/Sales ratio for Citius Oncology, Inc. (CTOR) demonstrates growth potential driven by biologics patents for lymphoma treatment, with the value holding around 6500.70. Future earnings are based on the results of clinical trials for targeted drugs. Cost optimization is achieved by outsourcing production to third-party facilities while maintaining research centers within the US.

CTOR Citius Oncology, Inc. Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/20/2026)

CTOR (citiusonc.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Initial company analysis:Citius Oncology, Inc., CTOR
Product sample of Citius Oncology, Inc.

EV/Sales assesses the total enterprise value of the business, including debt, relative to the revenue generated. The current change in the EV/Sales ratio has reached 6500.70, reflecting market expectations for sales scaling. This metric demonstrates the efficiency of asset monetization without the influence of capital structure. The stability of this ratio confirms the maturity of the Citius Oncology (CTOR) strategy. The company's high authority in developing targeted blood cancer therapies ensures a sustainable fundamental valuation.

Competitor analysis for Citius Oncology, Inc.

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|Enterprise Value-to-Revenue Multiple SELLAS Life Sciences Group SLS|EV/Sales Multiple ACTU|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio